NASDAQ:AWH Aspira Women's Health Q1 2024 Earnings Report $0.08 -0.01 (-12.49%) As of 04/16/2025 Earnings HistoryForecast Aspira Women's Health EPS ResultsActual EPS-$0.39Consensus EPS -$0.36Beat/MissMissed by -$0.03One Year Ago EPS-$10.94Aspira Women's Health Revenue ResultsActual Revenue$2.15 millionExpected Revenue$2.10 millionBeat/MissBeat by +$50.00 thousandYoY Revenue GrowthN/AAspira Women's Health Announcement DetailsQuarterQ1 2024Date5/21/2024TimeBefore Market OpensConference Call DateWednesday, May 15, 2024Conference Call Time8:30AM ETUpcoming EarningsAspira Women's Health's Q1 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled on Wednesday, May 14, 2025 at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesConference Call AudioConference Call TranscriptPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Aspira Women's Health Q1 2024 Earnings Call TranscriptProvided by QuartrMay 15, 2024 ShareLink copied to clipboard.There are 7 speakers on the call. Operator00:00:00Good morning, ladies and gentlemen, and welcome to the Aspyrra Women's Health Incorporated First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen only mode. Following management's prepared remarks, we will open the call for your questions. As a reminder, this call is being recorded today. Before we begin, I would like to remind everyone that forward looking statements as defined under the Private Securities Litigation Reform Act of 1995 will be made during this call, including statements related to Aspire's expected future performance, future business prospects and future events or plans. Operator00:00:32Although the company believes that the expectations reflected in such forward looking statements are based upon reasonable assumptions, actual outcomes and results are subject to risks and uncertainties that could cause results to differ materially from those anticipated due to the impact of many factors beyond ASPIRO Women's Health Control. The company assumes no obligation to update or supplement any forward looking statements, whether as a result of new information, future events or otherwise, except as required by law. Participants are directed to the cautionary note set forth in today's press release as well as the risk factors set forth in Aspire's most recent annual Form 10 ks and quarterly report on Form 10 Q filed with the SEC for a description of factors that could cause actual results to differ from those anticipated in the forward looking statements. At this time, I'd like to turn the call over to Nicole Sanford, Chief Executive Officer. Please go ahead. Speaker 100:01:29Thank you, and welcome, everyone, to our Q1 2024 earnings conference call. With me today are Doctor. Sandy Milligan, our new President and Torsten Hombach, our Chief Financial Officer. I will begin with an overview of our strategy, execution and operations, followed by Sandy with an update on our development plans and Torsten with a review of our financials. We will then open the call for questions. Speaker 100:01:52Let me begin with our strategy and commercial execution this quarter. We were excited to see Overwatch grow by 114% to 1052 in the Q1 of 2024 over the same period last year, representing approximately 18% of total pets volume, which declined slightly to 5,829. This is important as we believe the largest opportunity for future growth rests with that develop an index of mass and potentially multiplying the total addressable market by more than 2 to 3 times that of a single use test. Overwatch is designed to help physicians determine the risk of cancer for women with potentially benign or indeterminate masses, something for which there is no other non invasive tool available. We believe the broad adoption of Overwatch will help women avoid unnecessary surgery for the benefit of patients, physicians and payers. Speaker 100:02:51In fact, data published just last week in the peer reviewed journal Frontiers in Medicine showed that physician accuracy in predicting malignancy would have improved by more than 400% had Overwatch been used for those patients. You'll hear more about the data shortly, but let's stop there for a minute and talk about the power of this paper. It clearly demonstrates overwatch's utility for physicians to improve the accuracy of their assessment of malignancy risk and offers an incredible benefit to premenopausal women who may have resorted to surgery in the past. These women face the onset of surgical menopause if their ovaries are removed causing a host of near and long term health risks due to the abrupt drop in circulating hormones compared to women that experience menopause naturally and gradually. Surgical menopause has been found to increase women's long term risk of cardiovascular disease, osteoporosis, Parkinson's disease and dementia to name a few. Speaker 100:03:47We believe this data will play a central role in driving adoption of Overwatch by both physicians and payers and are currently executing an aggressive campaign to share the paper and findings with our various stakeholders. We also saw the publication of data supporting periodic testing published in the peer reviewed journal Gynecologic Oncology earlier this month. The validation of Overwatch is a reliable test in the monitoring of ovarian cancer risk in women with indeterminate or low risk anexcel masses, especially in a prestigious journal for gynecologic oncology is a major milestone. Data in this analysis of over 500 women supports the use of Overwatch for monitoring masses over time, offering women and physicians peace of mind if they choose to avoid surgery when malignancy risk is low. Turning now to our commercial activities. Speaker 100:04:35Our team is more prepared than ever to take advantage of the expanded features of Overwatch. Our sales efficiency numbers continue to improve with volume per full time representative increasing 22% to 364 in the Q1 this year when compared to the Q1 of last year. In addition, March was the strongest month of the Q1 and the momentum has carried into April, which was the 2nd largest volume month in company history despite 2 remaining open territories. Another key factor to growth is average unit pricing or AUP, which was at $3.69 for the quarter, consistent with the 1st full quarter of last year. Importantly, the volatility we anticipated with the launch of Overwatch never materialized, and our gross margin remains strong at 56%. Speaker 100:05:22Moving to an update on innovation. We are aggressively seeking alternative sources of funding for our product development, including the pursuit of research grants under the leadership of our new President, Sandy Milligan. We submitted ARPA H grants for OvaMDx and EndoMDx last month to take advantage of the opportunity to obtain funds made available by the Biden administration to support women's health research. The ARPA H grant process is expected to be condensed with funding decisions to be made as early as Q4. Other grant applications have been submitted for our portfolio, some of which have been submitted in partnership with collaborators. Speaker 100:05:58In addition to an NIH grant submitted by Dana Farber Cancer Institute, our EndoCheck test was included in a 3rd ARPA H grant proposal submitted by a scientific researcher that owns a patent that may be used in a promising drug therapy for the treatment of endometrioma. Endocheck is the only non invasive test that has been shown to accurately identify endometrioma, making it the perfect pairing for a combined solution and collaboration on clinical research. Positioning EndoCheck as a research test in this manner may generate income while simultaneously validating the algorithm. I continue to believe in the promise of EndoCheck as an inexpensive, non invasive tool for women with suspected endometrioma, especially for women with comorbidities that create higher surgical risk, adolescents and underinsured patients. However, we need to be smart about how we build the market to meet the needs of clinicians as well as patients. Speaker 100:06:52We are extraordinarily conscious of our spending. And while we would like to fully fund all of our programs, we must be thoughtful in deciding where our research dollars go. While we are pursuing alternative sources of funding for EndoTech, we are focusing our attention on the MDx portfolio. Now it is my pleasure to turn the call over to Doctor. Sandy Milligan, who joined us just a month ago. Speaker 100:07:13Her impact is already being felt throughout the organization, providing incredible insight, expertise, leadership and relationships. Sandy brings a refreshing discipline from her years in the military, a depth of medical knowledge from training as a physician and strategic clarity from her prior senior roles with a variety of market leading life sciences companies. She has been a tremendous addition to the team. I will now turn the call over to her. Speaker 200:07:38Thank you, Nicole, and it is truly my pleasure to be part of the Aspira team. It has been an exhilarating ride so far and I see tremendous potential in our science and technical expertise to forward our vision of transforming gynecological health. Since joining, my focus has been on understanding our programs and strategies to accelerate product development by confirming our priorities, timelines and capabilities to accelerate our progress without sacrificing scientific or technical rigor. Building on what Nicole has already shared about EndoCheck, we have continued to make strides with the scientific and clinical support for the test. From our previous work with ovarian cancer, we saw potential correlation between some protein biomarkers and endometriosis. Speaker 200:08:26We utilized AI to develop an algorithm and trained it on our internal dataset composed of women with adnexal masses where this algorithm had high performance. We then applied the algorithm to an external data set that included both patients with and without adnexal masses. In this cohort, we found that the signature had superior performance in the presence of endometriomas and superficial ovarian endometriosis, representing subtypes that are present in up to 40% of women diagnosed with endometriosis. We presented data related to the performance of EndoCheck for the identification of endometrioma at the Society of Reproductive Investigation Annual Scientific Meeting in February, where there was a great deal of excitement about EndoCheck from clinical, academic and other attendees for its potential contribution to a test with a broader application and the insights it offers to improve the understanding of this devastating and complex disease. Also, as Nicole mentioned, we announced the publication of 2 Overwatch focused manuscripts earlier this month. Speaker 200:09:38Collectively, the study support the use of Overwatch as a repeat ovarian cancer risk assessment tool and demonstrated the potential for significantly improved triaging of malignancies for surgery and clinical impression alone. Our published data demonstrates that Overwatch could substantially reduce surgeries for low risk patients performed out of concern for malignancy risk, especially for asymptomatic and premenopausal women. Indeed, Overwatch may have reduced the number of surgeries in women with low risk of malignancy by 62% in all patients and 77% in premenopausal women. With the added feature of serial monitoring, Overwatch can be drawn at provider prescribed intervals for active surveillance of an adnexal mass determined by initial clinical assessment as indeterminate or low risk. This is the strongest clinical support for OVA Watch and its value proposition for physicians and patients to date. Speaker 200:10:39Moving on to OvaMDx, which is being developed in collaboration with the Dana Farber Cancer Institute, we have completed assay analytical feasibility on an FDA approved PCR system and are nearing completion of our initial test design. This is a major innovation and a critical step in the development of our next generation test for ovarian cancer risk. We believe that the performance of the miRNAs we have licensed from Dana Farber will lead to the development of a commercial application. As we have shared previously, we believe this test will have the power to improve sensitivity for early stage ovarian cancer as well as specificity for histological subtypes solidifying our position as the leader in non invasive ovarian cancer testing for women with adnexal masses. Primarily leveraging samples from our existing biobank, we expect to complete the design and assay verification by the end of 2024. Speaker 200:11:39EndoMDx is also being developed in collaboration with Dana Farber. We will begin establishing analytical feasibility and down selecting of miRNA and protein candidates as part of the ongoing test design. By the end of 2024, we expect to complete the assay and algorithm design inputs and begin the verification and validation procedures, leveraging our experience developing OvaMDx and confidence in the signature delivery by Dana Farber. On the regulatory front, earlier this month, FDA finalized its rule to regulate lab developed tests. It is worth noting that unlike earlier proposals, it included provisions that may allow existing LDTs to be exempted from additional oversight provisions. Speaker 200:12:24We do not anticipate the new rule to have any impact on our ability to offer existing products, including the longitudinal testing feature of Overwatch. We are still assessing the impact of the final rule on the regulatory strategy for products in our pipeline. However, we do not currently anticipate this regulation to cause significant extension of our prior development or launch timelines. I want to thank everyone in the company for the reception I have received since joining. It is clear that everyone here is committed to the success of the company and to making a difference in women's health, and I am honored to be working alongside our talented crew. Speaker 200:13:03The passion for leading the way in women's health with non invasive AI enabled tests to aid in the diagnosis of gynecological diseases is unwavering and truly inspiring. With that, let me turn it over to Thorsten for an update on our financials. Speaker 300:13:20Thank you, Sandy. Let me begin with a review of our Q1 2024 financial results. Oversuite revenue for the Q1 of 2024 was $2,200,000 which was a slight decline from the $2,300,000 in the same period last year, but an increase of approximately $100,000 from the $2,100,000 from the Q4 of 2023. Revenue in the quarter benefited by strong 114% year over year growth of Overwatch, but was offset by a decrease in our OVA1 plus test volume that had been contributed by unprofitable territories eliminated as part of the refresh of our commercial strategy in 2023. Looking more closely at our sales trend this year, I'm very pleased to see our commercial refresh having a positive impact that we anticipated it would. Speaker 300:14:20We completed the refresh towards the end of last year. And importantly, we're now seeing a return to growth in test volume. As a matter of fact, our OvisSuite test volumes since January of 2024 have increased each month, both for OVA1 plus and Overwatch. And we have seen that positive trend continue into April. I do not normally comment on the monthly trends and we won't provide monthly updates in the future, but I felt it was important this quarter to demonstrate the reversal of the prior trends, which are now pointing again towards positive growth. Speaker 300:15:01Our overall average unit price was stable at $3.69 for the Q1 of 2024 compared to $3.70 in the Q1 of last year. However, the AUP number alone doesn't tell the whole story. Last year's Q1 was almost all related to OVA1 plus compared to this quarter where volume was closer to an eightytwenty split between OVER1 plus and OVERWATCH. The stable AUP means the average price of OVERWATCH is increasing and conforming with OVA1 plus faster than we had originally anticipated. We have seen no dilution in the price as a result of the change in product mix, which is normally expected with the launch of a new test. Speaker 300:15:52With the recent announcement of commercial reimbursement wins for Overstreet, like Ansemond, California, we believe our AUP will improve steadily. Our gross margins for the Q1 of 2024 improved to 56.3% compared to 51.2% in the Q1 of 2023. Our operating expenses all showed significant improvement this quarter compared to the Q1 of 2023. Research and development expenses for the quarter decreased by 28% and sales and marketing expenses decreased by 27%, while G and A decreased 13% as a result of our continued focus on disciplined spending throughout the organization. Our cash used in operating activities in the Q1 of 2023 was $4,400,000 down 23% compared to cash used in operating activities of $5,700,000 in the Q1 of 2023. Speaker 300:16:58Cash and restricted cash as of March 31, 2024 was $3,700,000 up from $2,900,000 as of December 31, 2023. To date, we have used $2,000,000 from our existing equity line of credit with Lincoln Park Capital, and we have approximately 2 point $8,000,000 remaining available to us. Additionally, we are pursuing various dilutive and non dilutive sources of funding, including research grants. We reiterate our cash used in operations guidance for 2024 to be between $15,000,000 $18,000,000 On a macro level, we see a clear resurgence of interest in women's health, including and maybe especially with respect to advanced diagnostic tools. I believe this was the publication of our 2 papers Nicole and Sandy talked about earlier and the expansion of Overwatch and its potential to provide a source of recurring revenue has strengthened our positioning in the market and with potential partners. Speaker 300:18:07While conditions continue to be less than optimal for small cap companies, I'm encouraged by the conversations we are having with various parties, including potential investors about the company. With that, I will now turn the call back over to Nicole for our closing remarks. Nicole? Speaker 100:18:28Thank you, Thorsten. ASPIDER remains steadfastly focused on its mission to improve health outcomes for millions of women, while positioning ourselves for long term success. We have the only blood test on the market for the accurate assessment of the risk of malignancy for all patients that have been diagnosed within the Nexo mass, and we are leading the way in the development of non invasive tests for endometriosis. With the launch of the longitudinal monitoring feature of Overwatch complete, the return of volume growth at the end of the Q1 and into the start of the second quarter, I'm more bullish than ever about our ability to scale the business. Despite the ongoing challenges in the market, we have kept our promises to patients, physicians and our shareholders to the best of our ability. Speaker 100:19:12Spirits in the company are high and we remain deeply committed to realizing the opportunities in front of us. With that, I would like to open the call for questions. Operator? Operator00:19:25Thank you. We will now be conducting a question and answer session. Our first question is from Ross Osborne with Cantor Fitzgerald. Please proceed with your question. Speaker 400:20:00Hi, good morning. Congrats on the progress. Thanks for taking our questions. So starting off, would you remind us to the extent that Overwatch LM will cannibalize the single monitoring offering? Speaker 100:20:14Sure. So, hey Ross, thanks for joining. It's really not a question of cannibalizing because this is extending the usage. So the single use test will continue to be and again, just a reminder to all that this is an additional feature. The test itself hasn't changed. Speaker 100:20:31So it's the same test, okay, just to be perfectly clear. It's a new feature that is supported by some pretty powerful clinical data that will encourage physicians to run the test multiple times for the same patient over time. So that first test will still be the first test, just like always. And now the physicians will be encouraged or will be able to select their own intervals for running additional tests. So this is a multiplier. Speaker 100:21:02It's not really a divider, let's say. Is that helpful? Speaker 400:21:08Yes. Understood. And then moving on to volume, you mentioned March being the strongest month of the quarter with momentum carrying into April. Would you just provide some more color on what's driving growth? Speaker 100:21:20Sure. Well, a few things. I think we've talked in the past about our commercial refresh. We've completed most of that work at this time and that included improving our messaging, providing additional tools to the team, creating a new marketing team. We added some folks who are focused on driving pull through with national accounts. Speaker 100:21:43We added some new people internally for inside sales. So there were a lot of different things that we've done over the course of the last year to improve the performance of the team. We also added a few roles in December. So we were close to a full team for the majority of the Q1. So we're really starting to see the momentum that we expected to see as a result of the changes that we made. Speaker 100:22:10So the downward trajectory in the second half of last year was a conscious decision to conserve cash by eliminating unprofitable territories, while we refreshed the entire commercial team in preparation for the launch of the longitudinal monitoring test, which we believe is the largest opportunity for the company and the company's history, frankly, for growth. Speaker 400:22:35Great. And then lastly for us, on the LDT proposal, are there any updates you'll need to do to your facilities to become compliant with the EA oversight? Speaker 100:22:46It's a little early for us to be 100% clear on the provisions. But Sandy, anything you want to comment there? Speaker 200:22:53Yes, certainly. I think there's some phase in responsibilities that we will have, but I think it will take any modifications to our already CLIA certified facilities. So there are some expected responsibilities around labeling, documentation, but nothing extraordinary and nothing that we're not prepared to do already. Speaker 400:23:15Okay, great. Thanks for taking our questions. Speaker 100:23:18Thanks Ross. Operator00:23:21Thank you. Our next question is from Andrew Brackmann with William Blair. Please proceed with your question. Speaker 500:23:29Hey, everyone. This is Maggie Bui on for Andrew today. Maybe one just to start on Overwatch growth. Can you talk about how much of the growth in the quarter from Overwatch came from new accounts versus driving utilization in existing accounts? And then while I can appreciate it's still early, what are you seeing in terms of new versus existing accounts with the recent longitudinal monitoring launch? Speaker 100:23:55Hey, Maggie. Thanks for joining. I don't think we've ever talked about or at least in recent history, we haven't talked about new versus existing physicians. So I'm not really prepared to give any additional color about that. And it is very early. Speaker 100:24:12In fact, it's less than a week since we launched the longitudinal monitoring application. So definitely too early to give too much color. I want to tell you though, this is to me is an important development, not just for the fact of driving recurring revenue, But we think that the Overwatch Longitude Monitoring test is going to help to create stickiness with our existing providers. What's important is that we have tests now that will be appropriate for assessing malignancy risk for every single patient that comes in the door with an Anexo mask. And so it will just become part of the standard procedure that physicians use when they have a patient with an Anexo mask and having that continuous ability to monitor it is a big part of driving adoption. Speaker 100:25:01Doctors really like to see those patients back. Periodically, they will often have them come back and have a follow-up ultrasound. We believe over time, the ultrasound and the Overwatch test will be ordered at the same time for the follow-up. Speaker 500:25:21Okay, great. Thank you. And then could you expand on the recent Anthem update and then provide some more color on what you're expecting in terms of timing of potential coverage and contracts to come through? Speaker 100:25:38Sure. Thorsten, do you want me to cover that or are you able to comment? Speaker 300:25:43Yes. So with Anthem, we signed the first agreement, which covered the Blue Crosses of California, which added approximately 6,000,000 covered lives to our portfolio. We are in the process of credentialing with Anthem for additional territories, and we would expect the next step to be seen in the next few weeks? Speaker 100:26:09The plan there is to continue to add contracts. Sorry, Maggie. So the plan will be to continue to add contracts. The way that Anthem works is, it really has to kind of go region by region, contract by contract. But our plan is to do what we can to focus our energies on areas of the country where we have volumes so that we can get the most bang for the buck in terms of those additional contracts. Speaker 100:26:35But one of the main keys is that we are credentialed now And it's for Ovisuite, which is the first time that we've been able to say that we have credentialing and contracting for the entire suite versus a Speaker 500:26:50single test. Makes sense. Thanks so much for taking our questions today. Speaker 100:26:56Sure. Thanks Maggie. Operator00:26:58Thanks Maggie. Our next question is from Do Kim with Water Tower Research. Please proceed with your question. Speaker 600:27:14Hi, good morning. Thanks for taking our questions. First question on for the longitudinal monitoring of Overwatch, how often or is there an expected frequency of repeat testing, testing, optimal time between tests or is it dependent on the patient? And, does the reimbursement coverage have limitations in the number of testing? Speaker 100:27:48So we made a very conscious decision not to prescribe a certain interval. What we found in our research was that individual physicians and healthcare providers have sort of their own judgment that they apply to how often they want to see those patients. We did see in the research that the most frequently selected interval was timed with a ultrasound, which was somewhere between 3 6 months. So that's going to be up to the physician. Of course, a lot of things can change between that first draw. Speaker 100:28:24So we're going to continue to study, but doctors were very clear to us that they didn't want to be told how often they ought to be drawing the test. They wanted that judgment to be in their hands as well. I'm sorry, Joe, can you repeat the second part of your question? Speaker 600:28:40Are there any limitations from insurance payers on the frequency or the number of testing allowed? Speaker 100:28:49Okay. No, we don't have anything in any their existing contracts that would restrict that. Speaker 600:28:54Okay, great. And how do you plan to use these publications and congrats on getting those studies published as an effective marketing tool? Speaker 100:29:08A few different ways. We've already trained the sales team on the outcomes of the studies. We've provided them with summaries of the studies and the full papers. They are out there talking to their existing ordering providers. We're also having our inside sales team reach out to physicians that have already used Overwatch to let them know that this feature is now available. Speaker 100:29:33So we're pretty aggressively going out there with that marketing side of things and also plan on hosting some virtual roundtables and KOL events. Speaker 600:29:47Great. And one last question, shifting over to the endometriosis testing. Do you have any updated thoughts on how the diagnosis of endometriosis is improving, the level of undiagnosed patients still out there? And how much overlap is there between your OVA suite marketing efforts, your sales force versus the endometriosis Operator00:30:20population? Speaker 100:30:22Well, I'll comment on that piece and then I'll ask Sandy if she has anything to add on the diagnosis landscape for endometriosis. Just the overlap is significant. Most of the physicians that will see patients that have pelvic pain or sort of consistent symptoms with things that drive them to use an overwatch tech. So it's the same physician typically, a gynecologist, a nurse practitioner, someone in OBGYN office will be most likely to be the first to identify the potential for all of these mass related and pain driven disease diagnoses. And Sandy, you can comment, but I would say that without our test, there really hasn't been any major innovation that's helping women to be diagnosed with endometriosis sooner at this point. Speaker 200:31:21Yes, I agree with you, Nicole. I think it's a great question. Do think the one area that we've seen an uptake is the additional conversation and awareness. So I think that patients are more generally aware of what their symptomatology could be, driving them to the physician's office. And so hopefully over time, we'll see that that standard accepted figure of 7 to 10 years of diagnosis starts to come down. Speaker 200:31:47However, as Nicole has pointed out, there isn't anything currently on the market, whether it's a diagnostic or an imaging study that has been qualified and certified or cleared for the diagnosis of endometriosis. So as it stands, the gold standard for the diagnosis of endometriosis is still an invasive laparoscopic surgery. So we're still moving towards better diagnostic capabilities. And of course, we're hoping that we will remain the front runner in that area. Speaker 100:32:23I'll add one thing to that. Thank you, Sandy. Dough, just one thing that we did recently in our marketing team, we went out and we took a look at the social media footprint for endometriosis focused groups, and particularly on Facebook and on Instagram. And we found a dozen that had literally 1000 and we had more than 4 or 5 that had more than 100,000 members. So this awareness is a really important part of our strategy when we roll out our first endometriosis test. Speaker 100:32:59There's an aggressive pull from the market for better diagnosis in endometriosis that I think could be incredibly valuable to us as we launch those tests. Speaker 600:33:11Absolutely agree. We're excited about your progress. Congrats on the quarter and thanks for taking our questions. Thank you, Do. Operator00:33:21At this time, there are no further questions in the queue. I will now turn it back to Nicole Sanford for closing remarks. Speaker 100:33:29Well, thank you everyone for joining us today. We look forward to continuing the progress of our execution and providing another update on our next quarterly earnings call. Thanks everyone. Operator00:33:43This concludes today's conference. You may disconnect your lines at this time. Thank you for your participation.Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallAspira Women's Health Q1 202400:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Aspira Women's Health Earnings HeadlinesAspira Women's Health Stock Triggers Heavy Retail Buzz On Nasdaq DelistingApril 18, 2025 | msn.comAspira Women's Health Inc. to Begin Trading April 17th On OTC Under the Symbol "AWHL"April 17, 2025 | gurufocus.comElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.May 4, 2025 | Brownstone Research (Ad)Aspira Women's Health Inc. to Begin Trading April 17th On OTC Under the Symbol ...April 17, 2025 | gurufocus.comAspira Women's Health Inc. Announces Receipt of Delisting Notification from NasdaqApril 16, 2025 | gurufocus.comAspira Women's Health: Aspira Appoints Three New Directors, Executes $2.0 Million Equity Purchase AgreementApril 8, 2025 | finanznachrichten.deSee More Aspira Women's Health Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aspira Women's Health? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aspira Women's Health and other key companies, straight to your email. Email Address About Aspira Women's HealthAspira Women's Health (NASDAQ:AWH), Inc. engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.View Aspira Women's Health ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Amazon Earnings: 2 Reasons to Love It, 1 Reason to Be CautiousMeta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2Palantir Earnings: 1 Bullish Signal and 1 Area of ConcernVisa Q2 Earnings Top Forecasts, Adds $30B Buyback PlanMicrosoft Crushes Earnings, What’s Next for MSFT Stock?Qualcomm's Earnings: 2 Reasons to Buy, 1 to Stay AwayAMD Stock Signals Strong Buy Ahead of Earnings Upcoming Earnings Palantir Technologies (5/5/2025)Vertex Pharmaceuticals (5/5/2025)Realty Income (5/5/2025)Williams Companies (5/5/2025)CRH (5/5/2025)Advanced Micro Devices (5/6/2025)American Electric Power (5/6/2025)Constellation Energy (5/6/2025)Marriott International (5/6/2025)Energy Transfer (5/6/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 7 speakers on the call. Operator00:00:00Good morning, ladies and gentlemen, and welcome to the Aspyrra Women's Health Incorporated First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen only mode. Following management's prepared remarks, we will open the call for your questions. As a reminder, this call is being recorded today. Before we begin, I would like to remind everyone that forward looking statements as defined under the Private Securities Litigation Reform Act of 1995 will be made during this call, including statements related to Aspire's expected future performance, future business prospects and future events or plans. Operator00:00:32Although the company believes that the expectations reflected in such forward looking statements are based upon reasonable assumptions, actual outcomes and results are subject to risks and uncertainties that could cause results to differ materially from those anticipated due to the impact of many factors beyond ASPIRO Women's Health Control. The company assumes no obligation to update or supplement any forward looking statements, whether as a result of new information, future events or otherwise, except as required by law. Participants are directed to the cautionary note set forth in today's press release as well as the risk factors set forth in Aspire's most recent annual Form 10 ks and quarterly report on Form 10 Q filed with the SEC for a description of factors that could cause actual results to differ from those anticipated in the forward looking statements. At this time, I'd like to turn the call over to Nicole Sanford, Chief Executive Officer. Please go ahead. Speaker 100:01:29Thank you, and welcome, everyone, to our Q1 2024 earnings conference call. With me today are Doctor. Sandy Milligan, our new President and Torsten Hombach, our Chief Financial Officer. I will begin with an overview of our strategy, execution and operations, followed by Sandy with an update on our development plans and Torsten with a review of our financials. We will then open the call for questions. Speaker 100:01:52Let me begin with our strategy and commercial execution this quarter. We were excited to see Overwatch grow by 114% to 1052 in the Q1 of 2024 over the same period last year, representing approximately 18% of total pets volume, which declined slightly to 5,829. This is important as we believe the largest opportunity for future growth rests with that develop an index of mass and potentially multiplying the total addressable market by more than 2 to 3 times that of a single use test. Overwatch is designed to help physicians determine the risk of cancer for women with potentially benign or indeterminate masses, something for which there is no other non invasive tool available. We believe the broad adoption of Overwatch will help women avoid unnecessary surgery for the benefit of patients, physicians and payers. Speaker 100:02:51In fact, data published just last week in the peer reviewed journal Frontiers in Medicine showed that physician accuracy in predicting malignancy would have improved by more than 400% had Overwatch been used for those patients. You'll hear more about the data shortly, but let's stop there for a minute and talk about the power of this paper. It clearly demonstrates overwatch's utility for physicians to improve the accuracy of their assessment of malignancy risk and offers an incredible benefit to premenopausal women who may have resorted to surgery in the past. These women face the onset of surgical menopause if their ovaries are removed causing a host of near and long term health risks due to the abrupt drop in circulating hormones compared to women that experience menopause naturally and gradually. Surgical menopause has been found to increase women's long term risk of cardiovascular disease, osteoporosis, Parkinson's disease and dementia to name a few. Speaker 100:03:47We believe this data will play a central role in driving adoption of Overwatch by both physicians and payers and are currently executing an aggressive campaign to share the paper and findings with our various stakeholders. We also saw the publication of data supporting periodic testing published in the peer reviewed journal Gynecologic Oncology earlier this month. The validation of Overwatch is a reliable test in the monitoring of ovarian cancer risk in women with indeterminate or low risk anexcel masses, especially in a prestigious journal for gynecologic oncology is a major milestone. Data in this analysis of over 500 women supports the use of Overwatch for monitoring masses over time, offering women and physicians peace of mind if they choose to avoid surgery when malignancy risk is low. Turning now to our commercial activities. Speaker 100:04:35Our team is more prepared than ever to take advantage of the expanded features of Overwatch. Our sales efficiency numbers continue to improve with volume per full time representative increasing 22% to 364 in the Q1 this year when compared to the Q1 of last year. In addition, March was the strongest month of the Q1 and the momentum has carried into April, which was the 2nd largest volume month in company history despite 2 remaining open territories. Another key factor to growth is average unit pricing or AUP, which was at $3.69 for the quarter, consistent with the 1st full quarter of last year. Importantly, the volatility we anticipated with the launch of Overwatch never materialized, and our gross margin remains strong at 56%. Speaker 100:05:22Moving to an update on innovation. We are aggressively seeking alternative sources of funding for our product development, including the pursuit of research grants under the leadership of our new President, Sandy Milligan. We submitted ARPA H grants for OvaMDx and EndoMDx last month to take advantage of the opportunity to obtain funds made available by the Biden administration to support women's health research. The ARPA H grant process is expected to be condensed with funding decisions to be made as early as Q4. Other grant applications have been submitted for our portfolio, some of which have been submitted in partnership with collaborators. Speaker 100:05:58In addition to an NIH grant submitted by Dana Farber Cancer Institute, our EndoCheck test was included in a 3rd ARPA H grant proposal submitted by a scientific researcher that owns a patent that may be used in a promising drug therapy for the treatment of endometrioma. Endocheck is the only non invasive test that has been shown to accurately identify endometrioma, making it the perfect pairing for a combined solution and collaboration on clinical research. Positioning EndoCheck as a research test in this manner may generate income while simultaneously validating the algorithm. I continue to believe in the promise of EndoCheck as an inexpensive, non invasive tool for women with suspected endometrioma, especially for women with comorbidities that create higher surgical risk, adolescents and underinsured patients. However, we need to be smart about how we build the market to meet the needs of clinicians as well as patients. Speaker 100:06:52We are extraordinarily conscious of our spending. And while we would like to fully fund all of our programs, we must be thoughtful in deciding where our research dollars go. While we are pursuing alternative sources of funding for EndoTech, we are focusing our attention on the MDx portfolio. Now it is my pleasure to turn the call over to Doctor. Sandy Milligan, who joined us just a month ago. Speaker 100:07:13Her impact is already being felt throughout the organization, providing incredible insight, expertise, leadership and relationships. Sandy brings a refreshing discipline from her years in the military, a depth of medical knowledge from training as a physician and strategic clarity from her prior senior roles with a variety of market leading life sciences companies. She has been a tremendous addition to the team. I will now turn the call over to her. Speaker 200:07:38Thank you, Nicole, and it is truly my pleasure to be part of the Aspira team. It has been an exhilarating ride so far and I see tremendous potential in our science and technical expertise to forward our vision of transforming gynecological health. Since joining, my focus has been on understanding our programs and strategies to accelerate product development by confirming our priorities, timelines and capabilities to accelerate our progress without sacrificing scientific or technical rigor. Building on what Nicole has already shared about EndoCheck, we have continued to make strides with the scientific and clinical support for the test. From our previous work with ovarian cancer, we saw potential correlation between some protein biomarkers and endometriosis. Speaker 200:08:26We utilized AI to develop an algorithm and trained it on our internal dataset composed of women with adnexal masses where this algorithm had high performance. We then applied the algorithm to an external data set that included both patients with and without adnexal masses. In this cohort, we found that the signature had superior performance in the presence of endometriomas and superficial ovarian endometriosis, representing subtypes that are present in up to 40% of women diagnosed with endometriosis. We presented data related to the performance of EndoCheck for the identification of endometrioma at the Society of Reproductive Investigation Annual Scientific Meeting in February, where there was a great deal of excitement about EndoCheck from clinical, academic and other attendees for its potential contribution to a test with a broader application and the insights it offers to improve the understanding of this devastating and complex disease. Also, as Nicole mentioned, we announced the publication of 2 Overwatch focused manuscripts earlier this month. Speaker 200:09:38Collectively, the study support the use of Overwatch as a repeat ovarian cancer risk assessment tool and demonstrated the potential for significantly improved triaging of malignancies for surgery and clinical impression alone. Our published data demonstrates that Overwatch could substantially reduce surgeries for low risk patients performed out of concern for malignancy risk, especially for asymptomatic and premenopausal women. Indeed, Overwatch may have reduced the number of surgeries in women with low risk of malignancy by 62% in all patients and 77% in premenopausal women. With the added feature of serial monitoring, Overwatch can be drawn at provider prescribed intervals for active surveillance of an adnexal mass determined by initial clinical assessment as indeterminate or low risk. This is the strongest clinical support for OVA Watch and its value proposition for physicians and patients to date. Speaker 200:10:39Moving on to OvaMDx, which is being developed in collaboration with the Dana Farber Cancer Institute, we have completed assay analytical feasibility on an FDA approved PCR system and are nearing completion of our initial test design. This is a major innovation and a critical step in the development of our next generation test for ovarian cancer risk. We believe that the performance of the miRNAs we have licensed from Dana Farber will lead to the development of a commercial application. As we have shared previously, we believe this test will have the power to improve sensitivity for early stage ovarian cancer as well as specificity for histological subtypes solidifying our position as the leader in non invasive ovarian cancer testing for women with adnexal masses. Primarily leveraging samples from our existing biobank, we expect to complete the design and assay verification by the end of 2024. Speaker 200:11:39EndoMDx is also being developed in collaboration with Dana Farber. We will begin establishing analytical feasibility and down selecting of miRNA and protein candidates as part of the ongoing test design. By the end of 2024, we expect to complete the assay and algorithm design inputs and begin the verification and validation procedures, leveraging our experience developing OvaMDx and confidence in the signature delivery by Dana Farber. On the regulatory front, earlier this month, FDA finalized its rule to regulate lab developed tests. It is worth noting that unlike earlier proposals, it included provisions that may allow existing LDTs to be exempted from additional oversight provisions. Speaker 200:12:24We do not anticipate the new rule to have any impact on our ability to offer existing products, including the longitudinal testing feature of Overwatch. We are still assessing the impact of the final rule on the regulatory strategy for products in our pipeline. However, we do not currently anticipate this regulation to cause significant extension of our prior development or launch timelines. I want to thank everyone in the company for the reception I have received since joining. It is clear that everyone here is committed to the success of the company and to making a difference in women's health, and I am honored to be working alongside our talented crew. Speaker 200:13:03The passion for leading the way in women's health with non invasive AI enabled tests to aid in the diagnosis of gynecological diseases is unwavering and truly inspiring. With that, let me turn it over to Thorsten for an update on our financials. Speaker 300:13:20Thank you, Sandy. Let me begin with a review of our Q1 2024 financial results. Oversuite revenue for the Q1 of 2024 was $2,200,000 which was a slight decline from the $2,300,000 in the same period last year, but an increase of approximately $100,000 from the $2,100,000 from the Q4 of 2023. Revenue in the quarter benefited by strong 114% year over year growth of Overwatch, but was offset by a decrease in our OVA1 plus test volume that had been contributed by unprofitable territories eliminated as part of the refresh of our commercial strategy in 2023. Looking more closely at our sales trend this year, I'm very pleased to see our commercial refresh having a positive impact that we anticipated it would. Speaker 300:14:20We completed the refresh towards the end of last year. And importantly, we're now seeing a return to growth in test volume. As a matter of fact, our OvisSuite test volumes since January of 2024 have increased each month, both for OVA1 plus and Overwatch. And we have seen that positive trend continue into April. I do not normally comment on the monthly trends and we won't provide monthly updates in the future, but I felt it was important this quarter to demonstrate the reversal of the prior trends, which are now pointing again towards positive growth. Speaker 300:15:01Our overall average unit price was stable at $3.69 for the Q1 of 2024 compared to $3.70 in the Q1 of last year. However, the AUP number alone doesn't tell the whole story. Last year's Q1 was almost all related to OVA1 plus compared to this quarter where volume was closer to an eightytwenty split between OVER1 plus and OVERWATCH. The stable AUP means the average price of OVERWATCH is increasing and conforming with OVA1 plus faster than we had originally anticipated. We have seen no dilution in the price as a result of the change in product mix, which is normally expected with the launch of a new test. Speaker 300:15:52With the recent announcement of commercial reimbursement wins for Overstreet, like Ansemond, California, we believe our AUP will improve steadily. Our gross margins for the Q1 of 2024 improved to 56.3% compared to 51.2% in the Q1 of 2023. Our operating expenses all showed significant improvement this quarter compared to the Q1 of 2023. Research and development expenses for the quarter decreased by 28% and sales and marketing expenses decreased by 27%, while G and A decreased 13% as a result of our continued focus on disciplined spending throughout the organization. Our cash used in operating activities in the Q1 of 2023 was $4,400,000 down 23% compared to cash used in operating activities of $5,700,000 in the Q1 of 2023. Speaker 300:16:58Cash and restricted cash as of March 31, 2024 was $3,700,000 up from $2,900,000 as of December 31, 2023. To date, we have used $2,000,000 from our existing equity line of credit with Lincoln Park Capital, and we have approximately 2 point $8,000,000 remaining available to us. Additionally, we are pursuing various dilutive and non dilutive sources of funding, including research grants. We reiterate our cash used in operations guidance for 2024 to be between $15,000,000 $18,000,000 On a macro level, we see a clear resurgence of interest in women's health, including and maybe especially with respect to advanced diagnostic tools. I believe this was the publication of our 2 papers Nicole and Sandy talked about earlier and the expansion of Overwatch and its potential to provide a source of recurring revenue has strengthened our positioning in the market and with potential partners. Speaker 300:18:07While conditions continue to be less than optimal for small cap companies, I'm encouraged by the conversations we are having with various parties, including potential investors about the company. With that, I will now turn the call back over to Nicole for our closing remarks. Nicole? Speaker 100:18:28Thank you, Thorsten. ASPIDER remains steadfastly focused on its mission to improve health outcomes for millions of women, while positioning ourselves for long term success. We have the only blood test on the market for the accurate assessment of the risk of malignancy for all patients that have been diagnosed within the Nexo mass, and we are leading the way in the development of non invasive tests for endometriosis. With the launch of the longitudinal monitoring feature of Overwatch complete, the return of volume growth at the end of the Q1 and into the start of the second quarter, I'm more bullish than ever about our ability to scale the business. Despite the ongoing challenges in the market, we have kept our promises to patients, physicians and our shareholders to the best of our ability. Speaker 100:19:12Spirits in the company are high and we remain deeply committed to realizing the opportunities in front of us. With that, I would like to open the call for questions. Operator? Operator00:19:25Thank you. We will now be conducting a question and answer session. Our first question is from Ross Osborne with Cantor Fitzgerald. Please proceed with your question. Speaker 400:20:00Hi, good morning. Congrats on the progress. Thanks for taking our questions. So starting off, would you remind us to the extent that Overwatch LM will cannibalize the single monitoring offering? Speaker 100:20:14Sure. So, hey Ross, thanks for joining. It's really not a question of cannibalizing because this is extending the usage. So the single use test will continue to be and again, just a reminder to all that this is an additional feature. The test itself hasn't changed. Speaker 100:20:31So it's the same test, okay, just to be perfectly clear. It's a new feature that is supported by some pretty powerful clinical data that will encourage physicians to run the test multiple times for the same patient over time. So that first test will still be the first test, just like always. And now the physicians will be encouraged or will be able to select their own intervals for running additional tests. So this is a multiplier. Speaker 100:21:02It's not really a divider, let's say. Is that helpful? Speaker 400:21:08Yes. Understood. And then moving on to volume, you mentioned March being the strongest month of the quarter with momentum carrying into April. Would you just provide some more color on what's driving growth? Speaker 100:21:20Sure. Well, a few things. I think we've talked in the past about our commercial refresh. We've completed most of that work at this time and that included improving our messaging, providing additional tools to the team, creating a new marketing team. We added some folks who are focused on driving pull through with national accounts. Speaker 100:21:43We added some new people internally for inside sales. So there were a lot of different things that we've done over the course of the last year to improve the performance of the team. We also added a few roles in December. So we were close to a full team for the majority of the Q1. So we're really starting to see the momentum that we expected to see as a result of the changes that we made. Speaker 100:22:10So the downward trajectory in the second half of last year was a conscious decision to conserve cash by eliminating unprofitable territories, while we refreshed the entire commercial team in preparation for the launch of the longitudinal monitoring test, which we believe is the largest opportunity for the company and the company's history, frankly, for growth. Speaker 400:22:35Great. And then lastly for us, on the LDT proposal, are there any updates you'll need to do to your facilities to become compliant with the EA oversight? Speaker 100:22:46It's a little early for us to be 100% clear on the provisions. But Sandy, anything you want to comment there? Speaker 200:22:53Yes, certainly. I think there's some phase in responsibilities that we will have, but I think it will take any modifications to our already CLIA certified facilities. So there are some expected responsibilities around labeling, documentation, but nothing extraordinary and nothing that we're not prepared to do already. Speaker 400:23:15Okay, great. Thanks for taking our questions. Speaker 100:23:18Thanks Ross. Operator00:23:21Thank you. Our next question is from Andrew Brackmann with William Blair. Please proceed with your question. Speaker 500:23:29Hey, everyone. This is Maggie Bui on for Andrew today. Maybe one just to start on Overwatch growth. Can you talk about how much of the growth in the quarter from Overwatch came from new accounts versus driving utilization in existing accounts? And then while I can appreciate it's still early, what are you seeing in terms of new versus existing accounts with the recent longitudinal monitoring launch? Speaker 100:23:55Hey, Maggie. Thanks for joining. I don't think we've ever talked about or at least in recent history, we haven't talked about new versus existing physicians. So I'm not really prepared to give any additional color about that. And it is very early. Speaker 100:24:12In fact, it's less than a week since we launched the longitudinal monitoring application. So definitely too early to give too much color. I want to tell you though, this is to me is an important development, not just for the fact of driving recurring revenue, But we think that the Overwatch Longitude Monitoring test is going to help to create stickiness with our existing providers. What's important is that we have tests now that will be appropriate for assessing malignancy risk for every single patient that comes in the door with an Anexo mask. And so it will just become part of the standard procedure that physicians use when they have a patient with an Anexo mask and having that continuous ability to monitor it is a big part of driving adoption. Speaker 100:25:01Doctors really like to see those patients back. Periodically, they will often have them come back and have a follow-up ultrasound. We believe over time, the ultrasound and the Overwatch test will be ordered at the same time for the follow-up. Speaker 500:25:21Okay, great. Thank you. And then could you expand on the recent Anthem update and then provide some more color on what you're expecting in terms of timing of potential coverage and contracts to come through? Speaker 100:25:38Sure. Thorsten, do you want me to cover that or are you able to comment? Speaker 300:25:43Yes. So with Anthem, we signed the first agreement, which covered the Blue Crosses of California, which added approximately 6,000,000 covered lives to our portfolio. We are in the process of credentialing with Anthem for additional territories, and we would expect the next step to be seen in the next few weeks? Speaker 100:26:09The plan there is to continue to add contracts. Sorry, Maggie. So the plan will be to continue to add contracts. The way that Anthem works is, it really has to kind of go region by region, contract by contract. But our plan is to do what we can to focus our energies on areas of the country where we have volumes so that we can get the most bang for the buck in terms of those additional contracts. Speaker 100:26:35But one of the main keys is that we are credentialed now And it's for Ovisuite, which is the first time that we've been able to say that we have credentialing and contracting for the entire suite versus a Speaker 500:26:50single test. Makes sense. Thanks so much for taking our questions today. Speaker 100:26:56Sure. Thanks Maggie. Operator00:26:58Thanks Maggie. Our next question is from Do Kim with Water Tower Research. Please proceed with your question. Speaker 600:27:14Hi, good morning. Thanks for taking our questions. First question on for the longitudinal monitoring of Overwatch, how often or is there an expected frequency of repeat testing, testing, optimal time between tests or is it dependent on the patient? And, does the reimbursement coverage have limitations in the number of testing? Speaker 100:27:48So we made a very conscious decision not to prescribe a certain interval. What we found in our research was that individual physicians and healthcare providers have sort of their own judgment that they apply to how often they want to see those patients. We did see in the research that the most frequently selected interval was timed with a ultrasound, which was somewhere between 3 6 months. So that's going to be up to the physician. Of course, a lot of things can change between that first draw. Speaker 100:28:24So we're going to continue to study, but doctors were very clear to us that they didn't want to be told how often they ought to be drawing the test. They wanted that judgment to be in their hands as well. I'm sorry, Joe, can you repeat the second part of your question? Speaker 600:28:40Are there any limitations from insurance payers on the frequency or the number of testing allowed? Speaker 100:28:49Okay. No, we don't have anything in any their existing contracts that would restrict that. Speaker 600:28:54Okay, great. And how do you plan to use these publications and congrats on getting those studies published as an effective marketing tool? Speaker 100:29:08A few different ways. We've already trained the sales team on the outcomes of the studies. We've provided them with summaries of the studies and the full papers. They are out there talking to their existing ordering providers. We're also having our inside sales team reach out to physicians that have already used Overwatch to let them know that this feature is now available. Speaker 100:29:33So we're pretty aggressively going out there with that marketing side of things and also plan on hosting some virtual roundtables and KOL events. Speaker 600:29:47Great. And one last question, shifting over to the endometriosis testing. Do you have any updated thoughts on how the diagnosis of endometriosis is improving, the level of undiagnosed patients still out there? And how much overlap is there between your OVA suite marketing efforts, your sales force versus the endometriosis Operator00:30:20population? Speaker 100:30:22Well, I'll comment on that piece and then I'll ask Sandy if she has anything to add on the diagnosis landscape for endometriosis. Just the overlap is significant. Most of the physicians that will see patients that have pelvic pain or sort of consistent symptoms with things that drive them to use an overwatch tech. So it's the same physician typically, a gynecologist, a nurse practitioner, someone in OBGYN office will be most likely to be the first to identify the potential for all of these mass related and pain driven disease diagnoses. And Sandy, you can comment, but I would say that without our test, there really hasn't been any major innovation that's helping women to be diagnosed with endometriosis sooner at this point. Speaker 200:31:21Yes, I agree with you, Nicole. I think it's a great question. Do think the one area that we've seen an uptake is the additional conversation and awareness. So I think that patients are more generally aware of what their symptomatology could be, driving them to the physician's office. And so hopefully over time, we'll see that that standard accepted figure of 7 to 10 years of diagnosis starts to come down. Speaker 200:31:47However, as Nicole has pointed out, there isn't anything currently on the market, whether it's a diagnostic or an imaging study that has been qualified and certified or cleared for the diagnosis of endometriosis. So as it stands, the gold standard for the diagnosis of endometriosis is still an invasive laparoscopic surgery. So we're still moving towards better diagnostic capabilities. And of course, we're hoping that we will remain the front runner in that area. Speaker 100:32:23I'll add one thing to that. Thank you, Sandy. Dough, just one thing that we did recently in our marketing team, we went out and we took a look at the social media footprint for endometriosis focused groups, and particularly on Facebook and on Instagram. And we found a dozen that had literally 1000 and we had more than 4 or 5 that had more than 100,000 members. So this awareness is a really important part of our strategy when we roll out our first endometriosis test. Speaker 100:32:59There's an aggressive pull from the market for better diagnosis in endometriosis that I think could be incredibly valuable to us as we launch those tests. Speaker 600:33:11Absolutely agree. We're excited about your progress. Congrats on the quarter and thanks for taking our questions. Thank you, Do. Operator00:33:21At this time, there are no further questions in the queue. I will now turn it back to Nicole Sanford for closing remarks. Speaker 100:33:29Well, thank you everyone for joining us today. We look forward to continuing the progress of our execution and providing another update on our next quarterly earnings call. Thanks everyone. Operator00:33:43This concludes today's conference. You may disconnect your lines at this time. Thank you for your participation.Read morePowered by